Picard Medical, Inc. (PMI)

Picard Medical, Inc. is the parent company of SynCardia Systems, the developer and manufacturer of the SynCardia Total Artificial Heart. The device replaces both failing ventricles and the heart valves, and is used to support patients with end-stage biventricular heart failure, most often as a bridge while they wait for a donor heart transplant.

The SynCardia heart is implanted in hospitals in the United States and other countries and is powered by an external pneumatic driver, including a portable version that can allow some patients to leave the hospital while awaiting transplant. The company sells the implant, drivers and related services to transplant and heart failure centers and continues to develop next-generation, fully implantable and electrically driven artificial heart technology.

Picard Medical is headquartered in Tucson, Arizona, and completed its initial public offering in 2025. Its common stock trades on NYSE American under the ticker PMI.